Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.39 |
| ▸ | GPR55 | Q9Y2T6 | 3/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 8/20 | 0.35 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | EGFR | P00533 | 1/20 | 0.34 |
| ▸ | ATM | Q13315 | 2/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | P4HB | P07237 | 1/20 | 0.33 |
| ▸ | AVPR1B | P47901 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10313689 | 0.87 | MEN1 (0.41) | MEN1KMT2AGPR55PKMMAPT | |
| SCHEMBL10275902 | 0.87 | NPSR1 (0.42) | MEN1KMT2AGPR55PKMMAPT | |
| SCHEMBL10313697 | 0.85 | KMT2A (0.39) | MEN1KMT2AGPR55PKMMAPT | |
| SCHEMBL10275583 | 0.85 | MEN1 (0.38) | MEN1KMT2AGPR55PKMMAPT | |
| SCHEMBL10275522 | 0.84 | LNPEP (0.42) | MEN1KMT2AGPR55PKMMAPT | |
| SCHEMBL10276275 | 0.82 | MEN1 (0.36) | MEN1KMT2AGPR55PKMMAPT | |
| SCHEMBL10276274 | 0.80 | MEN1 (0.36) | MEN1KMT2AGPR55PKMMAPT | |
| SCHEMBL10275696 | 0.78 | NPSR1 (0.38) | NPSR1EGFRAVPR1B | |
| SCHEMBL10313468 | 0.78 | MYB (0.54) | MEN1KMT2AMAPTTDP1NPSR1 | |
| SCHEMBL10313695 | 0.74 | MEN1 (0.41) | MEN1KMT2AGPR55PKMMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120178915-A1 | PYRIMIDINE DERIVATIVES AND ANALOGS, PREPARATION METHOD AND USE THEREOF | XU LIFENG (US) | 2012-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120178915-A1 | PYRIMIDINE DERIVATIVES AND ANALOGS, PREPARATION METHOD AND USE THEREOF | TYMP, TYMS, ADORA3 | MEN1 4229/4885KMT2A 4649/4885GPR55 2279/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.